Association between the difference in cystatin C and creatinine-based eGFR and risks of multiple cardiovascular diseases: a prospective cohort study

胱抑素C与基于肌酐的eGFR差异与多种心血管疾病风险之间的关联:一项前瞻性队列研究

阅读:2

Abstract

BACKGROUND: The difference between cystatin C- and creatinine-based estimated glomerular filtration rate (eGFR(diff)) is closely associated with various adverse outcomes. This study aims to comprehensively evaluate the association between eGFR(diff), all-cause mortality, and the risk of multiple cardiovascular-related diseases. METHODS: This study analyzed data from 297,140 participants in the UK Biobank to assess the association between eGFR(diff), mortality, and the incidence of multiple cardiovascular-related diseases. eGFR(diff) was classified into three groups: negative (< -15 mL/min/1.73 m(2)), intermediate (-15 to 15 mL/min/1.73 m(2)), and positive (≥ 15 mL/min/1.73 m(2)). Cox proportional hazards regression models were used to evaluate this association, while various sensitivity analyses were performed to assess its robustness. RESULTS: During a mean follow-up of 13.1 years, the positive eGFR(diff) group exhibited significantly lower mortality, cardiovascular disease (CVD) incidence, and the occurrence of CVD-related conditions. In the fully adjusted model, participants in the negative eGFR(diff) group had a hazard ratio of 1.44 (95% confidence interval [CI], 1.40-1.49) for all-cause mortality, 1.49 (95% CI, 1.41-1.59) for CVD incidence, and 1.25 (95% CI, 1.22-1.27) for CVD mortality. The risk of all 10 CVD-related conditions was also significantly higher in the negative group, whereas the positive group exhibited significantly lower risks. For every 10 mL/min/1.73 m(2) increase in eGFR(diff), the incidence of various diseases decreased by approximately 10-19%. CONCLUSION: eGFR(diff) is significantly associated with increased risks of mortality, CVD incidence, and multiple CVD-related conditions. These findings underscore the critical need for developing targeted prevention strategies, particularly for populations with reduced eGFR(diff).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。